Viglya wishes to establish transparent and open communication with its stakeholders. This section offers new and updated information regarding the company and the life science sector.
(Cas) AEMPS: Tofacitinib (▼Xeljanz): restricciones provisionales de uso por motivos de seguridad. Se contraindica el uso de 10 mg 2 veces al día en pacientes con alto riesgo de embolia pulmonar
Sorry, this entry is only available in European Spanish. For the sake of viewer convenience, the content is shown below in the alternative language. You may click the link to switch the active language. Los [...]
L’ensemble des parties prenantes s’est réuni le 14 mai 2019 pour faire un point d’étape sur l’impact de l’utilisation des dialysats sur la mortalité en France à partir des données disponibles, conformément à ce qui [...]
Today, the U.S. Food and Drug Administration is warning patients and health care professionals of risks associated with the use of unapproved or unauthorized devices for diabetes management, including continuous glucose monitoring systems, insulin pumps [...]
EMA’s safety committee (PRAC) has recommended that the marketing authorisations for fenspiride medicines be revoked, so the medicines can no longer be marketed in the EU. This follows a review that has confirmed that these cough medicines [...]
Restrictions in use of Xeljanz while PRAC reviews risk of blood clots in lungs EMA’s safety committee (PRAC) has started a new review of Xeljanz (tofacitinib) and has recommended, as a temporary measure during the review, that [...]
EMA’s safety committee (PRAC) is recommending that doctors must not prescribe the 10 mg twice daily dose of Xeljanz (tofacitinib) in patients who are at high risk of blood clots in the lungs. These include [...]